Melanoma has no single, predictable timetable for spreading. Some melanomas remain confined to the skin for years, growing outward slowly enough that early removal is curative. Others burrow deeper and reach lymph nodes or distant organs within months. The speed depends on the melanoma’s subtype, its thickness at the time of diagnosis, the individual’s biology, and a measure of biological luck that researchers are still working to decode. What the evidence does make clear is that depth matters enormously, and that the window between “curable with surgery alone” and “capable of spreading” can be surprisingly narrow for aggressive subtypes.
How Fast Different Melanoma Types Grow
Not all melanomas grow at the same pace. The most common form, superficial spreading melanoma, tends to expand outward across the skin’s surface for months or even years before it starts pushing deeper. This outward phase is sometimes called the radial growth phase, and while the tumor is confined to it, the risk of spread is low. Lentigo maligna melanoma, which typically appears on sun-damaged skin in older adults, behaves similarly, often lingering for years as a flat, irregular patch.
Nodular melanoma is the alarming exception. It largely skips the horizontal phase and drives downward into the skin almost immediately. A study measuring monthly growth rates found that nodular melanomas thickened at a median rate of about 0.49 mm per month, roughly four times faster than superficial spreading melanomas at 0.12 mm per month or lentigo maligna melanomas at 0.13 mm per month.1JAMA Dermatology. Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas At that pace, a nodular melanoma can cross from thin (low-risk) to thick (high-risk) territory in just a few months. This is one reason why a new, rapidly growing, dome-shaped bump on the skin deserves urgent attention even if it doesn’t look like the “classic” irregularly shaped mole people are taught to watch for.
Thickness Is the Strongest Predictor of Spread
The single most important number in a melanoma pathology report is the Breslow thickness, a measurement in millimeters of how deep the tumor extends below the skin surface. The relationship between depth and the risk of lymph node involvement is roughly stepwise:
- In situ (confined to the top skin layer): negligible risk of spread to lymph nodes.
- Less than 0.75 mm: risk of lymph node involvement is under about 5%.
- 0.75 to 1.0 mm: risk climbs to roughly 5 to 10%, especially if the tumor is ulcerated or dividing quickly.
- 1.0 to 4.0 mm: the chance of microscopic spread to nearby lymph nodes runs about 15 to 25%, rising as thickness increases.
- Over 4.0 mm: lymph node involvement is found in roughly 25 to 40% of cases at the time of diagnosis.
These figures come from large datasets tracking sentinel lymph node biopsy results.2Australian Family Physician. Melanoma A management guide for GPs The implication is that many melanomas have already sent cells into the lymphatic system by the time they reach about 1 mm deep, and a sizable fraction of thick melanomas have done so by the time they are found. That doesn’t mean every thick melanoma has spread, but it shifts the conversation from “monitor and wait” to “look actively for evidence of metastasis.”
Certain features besides thickness also raise the alarm. Ulceration of the tumor surface, a high rate of cell division, and younger patient age have all been linked to higher odds of a positive sentinel lymph node biopsy even among thinner melanomas.3Skin. Sentinel Lymph Node Predictors in Melanoma of Breslow Thickness 0.8-1.0 mm
The Routes Melanoma Uses to Spread
Melanoma can travel two ways: through the lymphatic vessels to nearby lymph nodes, or through the bloodstream directly to distant organs. How those two routes interact has been debated for decades. One model holds that melanoma follows a stepwise path, first reaching the nearest lymph node and then, after a lag period, entering the blood to reach far-off sites. A competing model argues that lymphatic and blood-borne spread happen simultaneously, making lymph node involvement a marker rather than a gateway. A third model suggests that different melanomas simply have different biological capabilities, and some never gain the ability to metastasize at all while others can use both pathways independently.4JAMA Dermatology. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma
In practice, all three patterns appear to occur. Some patients develop lymph node disease first and distant disease later. Others skip the lymph nodes entirely and show up with, say, a lung or liver metastasis. The clinical takeaway is that a clean sentinel lymph node biopsy lowers the probability of distant spread but does not eliminate it. This is why follow-up monitoring includes periodic imaging and blood work, not just checking lymph nodes.
Dormancy Changes the Timeline Entirely
One of the more unsettling aspects of melanoma biology is dormancy. Tumor cells can leave the primary tumor, settle in distant tissue, and remain inactive for months, years, or even decades before waking up and growing into a detectable metastasis. Even the most effective surgeries and drug therapies rarely eliminate every last cancer cell; instead, they reduce the cancer burden to the point where surviving cells persist quietly in protective niches throughout the body.5PubMed Central. Dormancy of cutaneous melanoma
Dormant melanoma cells carry the same mutations that drove the original tumor, yet they do not actively divide, which makes them invisible to most treatments designed to kill rapidly growing cells. Researchers believe the signals that keep these cells asleep or wake them up come largely from the surrounding tissue environment rather than from changes within the cancer cell itself.6PubMed Central. Dormancy of metastatic melanoma What flips the switch remains an active area of investigation. Inflammation, immune suppression, aging, and shifts in the local tissue chemistry are all suspected triggers. For patients and doctors, dormancy means that melanoma recurrence five, ten, or even twenty years after the original diagnosis is not a fluke; it reflects a known biological capability of this disease.
Where Melanoma Tends to Go and How Quickly
When melanoma does spread to distant organs, the target matters for both prognosis and timing. Among distant organ sites beyond the lung, the liver is the most commonly affected, followed by the brain and then bone.7PubMed Central. Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors But the speed at which metastases appear in these organs varies. Brain metastases tend to develop relatively quickly, while liver metastases often take longer to emerge.
Genetic features of the tumor influence this timing. In patients with BRAF-mutated melanoma, loss of a tumor suppressor gene called PTEN was associated with brain metastases appearing at a median of about 1.8 years after advanced-stage diagnosis, compared with roughly 4.9 years in patients who retained PTEN function. The same genetic difference did not significantly alter the timing for lung, liver, or bone metastases.8Clinical Cancer Research. Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations This kind of molecular detail is increasingly being used to predict which patients are at highest risk for early, aggressive spread and to tailor surveillance accordingly.
Men and Women Follow Different Timelines
Sex appears to independently affect how fast melanoma spreads. Women develop their first metastasis later than men, with a median time of about 25 months compared with about 23 months for men. The gap widens for distant metastases: a median of roughly 40 months in women versus 33 months in men.9PLOS ONE. Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women Women also carry a lower overall risk of progression at every stage. One large analysis found that women had about a 30 to 40% lower hazard of developing lymph node or distant metastases, and they retained a survival advantage even after spread occurred.10Journal of Investigative Dermatology. Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis
The reasons are not fully pinned down. Research in animal models suggests sex hormones play a role: estrogen receptor activity appears to work against tumor aggressiveness, while testosterone may increase it.11PubMed Central. Sex Differences in Melanoma Differences in immune function between men and women may also contribute. Regardless of the mechanism, the pattern is robust enough that sex is considered when assessing a patient’s prognosis.
Surgical Delay Can Shift the Odds
Given how quickly some melanomas can thicken and reach a danger point, it’s reasonable to wonder whether delays in surgical treatment affect outcomes. The evidence says yes, particularly for early-stage disease. A systematic review found that seven out of ten included studies linked longer waits between biopsy and definitive surgery to lower overall survival.12PubMed. The Impact of Surgical Delay in Primary Cutaneous Melanoma: A Systematic Review
In one large study of over 400,000 patients, about a fifth experienced a surgical delay of 45 days or more. Those patients were more likely to have lymph node involvement and had lower overall survival.13PubMed. Association between surgical delay and outcomes among patients with invasive cutaneous melanoma A separate analysis using the National Cancer Database looked at more granular time windows and found that for stage I melanoma, mortality risk climbed steadily with longer delays: patients treated more than 119 days after biopsy had roughly a 40% higher risk of death compared with those treated within 30 days.14PubMed Central. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database
Interestingly, the same study found that surgical timing did not significantly affect survival in stages II and III. That could mean the damage is already done by the time thicker melanomas are found, or that the systemic therapies used for more advanced disease compensate for any delay. Either way, the message for thin, early melanomas is clear: get the surgery scheduled promptly.
Melanomas That Do Not Look Like Melanoma
Part of why melanoma sometimes reaches a dangerous thickness before being caught is that it doesn’t always look the way people expect. Amelanotic melanomas lack the characteristic brown or black pigment and may appear as pink or red bumps that get mistaken for eczema, fungal infections, or benign growths. In one study, melanoma was included in the initial clinical suspicion for only about a third of red amelanotic cases, compared with 94% of pigmented melanomas.15PubMed Central. Amelanotic Melanomas Presenting as Red Skin Lesions: A Diagnostic Challenge with Potentially Lethal Consequences More than half of those red amelanotic melanomas underwent a shave biopsy on initial presentation, and about three-quarters had incompletely removed lesions on first attempt. Deep margins were positive in 44% of amelanotic cases versus just 9% of pigmented ones.
These diagnostic delays and incomplete initial biopsies give amelanotic melanomas extra time to thicken and potentially spread before proper treatment begins. If you have a pink or reddish bump that is changing, growing, or not healing, the possibility of amelanotic melanoma is worth raising with a dermatologist.
How Growth Rate Predicts Outcomes Once Spread Has Occurred
Once melanoma has metastasized, how fast those metastases grow also matters. Researchers have quantified something called the metastatic growth rate, which measures how rapidly established metastatic deposits are enlarging. In patients with BRAF-mutated melanoma receiving targeted therapy, those whose metastases were growing faster than about 4 mm per month had strikingly worse outcomes: a median overall survival of roughly 11 months compared with about 35 months for patients with slower-growing metastases.16European Journal of Cancer. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy The growth rate was an independent predictor of survival, meaning it added prognostic information beyond what standard staging alone provided. Clinicians are increasingly factoring in how aggressively the disease is behaving, not just where it has traveled, when making treatment decisions.
Adjuvant Therapy to Delay or Prevent Spread
For patients whose melanoma has been surgically removed but carries a high risk of recurrence, adjuvant immunotherapy has changed the equation. Pembrolizumab, a checkpoint inhibitor, was tested against placebo in patients with resected stage III melanoma and reduced the risk of recurrence or death by roughly 43% at one year.17PubMed. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma More recently, a trial extended this concept to stage IIB and IIC melanoma, which are thicker tumors without detected lymph node involvement but with recurrence rates that rival some stage III cases. In that trial, pembrolizumab cut the risk of recurrence or death by roughly 35 to 39% over the study period.18The Lancet. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC resected melanoma (KEYNOTE-716)
These therapies don’t guarantee that dormant cells won’t eventually reactivate, and they come with side effects that require careful discussion. But they represent a meaningful tool for buying time and potentially preventing melanoma from ever reaching distant organs in a subset of patients. The expanding eligibility criteria reflect how seriously the field takes the risk of spread even in melanomas that appear to have been completely removed.
Catching Spread Before Scans Can See It
One of the more promising developments in melanoma monitoring involves blood-based detection of tumor DNA. When melanoma cells die, they release fragments of their DNA into the bloodstream. Measuring these fragments can pick up signs of tumor activity before conventional imaging shows anything. In a study of patients with metastatic melanoma, circulating tumor DNA analyses preceded the imaging-based diagnosis of progression by an average of about three and a half months.19Journal of Clinical Oncology. ctDNA as a noninvasive monitoring tool in metastatic melanoma About 80% of patients in that study had cases where the blood test flagged a change before scans did.
This kind of lead time could eventually allow earlier treatment adjustments, catching a relapse when the tumor burden is still tiny rather than waiting until a mass is visible on a CT or PET scan. Liquid biopsies are not yet standard of care for all melanoma patients, but they are increasingly used in clinical trials and specialized centers, and their role is expected to grow as costs fall and validation studies accumulate.